0.3395
price down icon3.88%   -0.0137
 
loading
Bioatla Inc stock is traded at $0.3395, with a volume of 382.75K. It is down -3.88% in the last 24 hours and up +4.21% over the past month. BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.3532
Open:
$0.3638
24h Volume:
382.75K
Relative Volume:
0.43
Market Cap:
$19.83M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1311
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-9.37%
1M Performance:
+4.21%
6M Performance:
-83.28%
1Y Performance:
-90.36%
1-Day Range:
Value
$0.3368
$0.3638
1-Week Range:
Value
$0.283
$0.40
52-Week Range:
Value
$0.2806
$4.02

Bioatla Inc Stock (BCAB) Company Profile

Name
Name
Bioatla Inc
Name
Phone
858-558-0708
Name
Address
11085 TORREYANA ROAD, SAN DIEGO
Name
Employee
61
Name
Twitter
Name
Next Earnings Date
2025-03-21
Name
Latest SEC Filings
Name
BCAB's Discussions on Twitter

Compare BCAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BCAB
Bioatla Inc
0.3395 19.83M 0 -123.46M -104.11M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Bioatla Inc Stock (BCAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-13-24 Downgrade H.C. Wainwright Buy → Neutral
Sep-15-22 Initiated JMP Securities Mkt Outperform
May-05-22 Downgrade Credit Suisse Outperform → Neutral
Mar-21-22 Initiated H.C. Wainwright Buy
Oct-15-21 Resumed BTIG Research Buy
Jun-28-21 Initiated ROTH Capital Buy
May-05-21 Resumed Credit Suisse Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Jan-11-21 Initiated BTIG Research Buy
Jan-11-21 Initiated Credit Suisse Outperform
Jan-11-21 Initiated JP Morgan Overweight
Jan-11-21 Initiated Jefferies Buy
View All

Bioatla Inc Stock (BCAB) Latest News

pulisher
01:49 AM

FY2029 Earnings Estimate for BioAtla Issued By HC Wainwright - Defense World

01:49 AM
pulisher
Apr 01, 2025

BioAtla (NASDAQ:BCAB) Given “Neutral” Rating at HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

BioAtla stock price target cut to $1 by Citizens JMP - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025
pulisher
Mar 31, 2025

BioAtla price target lowered to $1 from $5 at Citizens JMP - TipRanks

Mar 31, 2025
pulisher
Mar 29, 2025

BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call Transcript - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

BioAtla stock price target cut to $10 at BTIG, retains Buy rating - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

BioAtla stock price target cut to $10 at BTIG, retains Buy rating By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

BioAtla Inc. (BCAB) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

BioAtla, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 27, 2025

BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

BioAtla announces restructuring, to cut over 30% of workforce - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

BioAtla reports Q4 Net loss ($14.9M) vs ($26.9M) last year - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Bioatla IncAnnounces 30% Workforce Reduction - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - The Manila Times

Mar 27, 2025
pulisher
Mar 26, 2025

Earnings Outlook For BioAtla - Benzinga

Mar 26, 2025
pulisher
Mar 20, 2025

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - Quantisnow

Mar 20, 2025
pulisher
Mar 20, 2025

BioAtla, Inc. Announces Abstract Presentations at European Lung Cancer Congress and Mayo Clinic Symposium 2025 - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

BioAtla Advances Cancer Research with Dual Presentations at Elite European and Mayo Clinic Conferences - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - Quantisnow

Mar 19, 2025
pulisher
Mar 19, 2025

BioAtla Earnings Alert: Key Q4 and 2024 Results Coming March 27What to Watch - Stock Titan

Mar 19, 2025
pulisher
Mar 18, 2025

BioAtla (BCAB) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Mar 17, 2025
pulisher
Mar 14, 2025

BioAtla Awards Executive Bonuses and Stock Units - TipRanks

Mar 14, 2025
pulisher
Mar 11, 2025

What Are You Thinking About Investing In BioAtla Inc (NASDAQ: BCAB) Stock? - stocksregister.com

Mar 11, 2025
pulisher
Mar 07, 2025

BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 12.6% in February - Defense World

Mar 07, 2025
pulisher
Feb 25, 2025

Bioatla stock hits 52-week low at $0.38 amid sharp decline By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Bioatla stock hits 52-week low at $0.38 amid sharp decline - Investing.com UK

Feb 25, 2025
pulisher
Feb 25, 2025

BioAtla Inc (BCAB) shows promising results - US Post News

Feb 25, 2025
pulisher
Feb 10, 2025

Market Momentum Report: BioAtla Inc (BCAB)’s Negative Close at 0.45 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

BioAtla Inc: Navigating a Turbulent Year, Up -88.84% from 52-Week Low - The InvestChronicle

Feb 10, 2025
pulisher
Feb 07, 2025

BioAtla faces Nasdaq delisting over share price rule - MSN

Feb 07, 2025
pulisher
Feb 07, 2025

BioAtla Inc (BCAB) Shares Down Despite Recent Market Volatility - The News Heater

Feb 07, 2025
pulisher
Jan 26, 2025

Millennium Management LLC Reduces Stake in BioAtla Inc. - GuruFocus.com

Jan 26, 2025
pulisher
Jan 15, 2025

Jane Street Group LLC Decreases Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

BioAtla (NASDAQ:BCAB) Stock Price Down 6.1% – Here’s Why - Defense World

Jan 14, 2025
pulisher
Jan 08, 2025

Bioatla stock hits 52-week low at $0.57 amid sharp decline - Investing.com

Jan 08, 2025
pulisher
Jan 07, 2025

Fierce Biotech Layoff Tracker 2025: BioAtla implements 30% RIF; Nkarta cuts 53 roles - Fierce Biotech

Jan 07, 2025
pulisher
Jan 02, 2025

BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Jan 02, 2025
pulisher
Dec 22, 2024

**BioAtla Updates Corporate Presentation in 8-K Filing** - Defense World

Dec 22, 2024

Bioatla Inc Stock (BCAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):